This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, provided a corporate update, including a clinical trial enrollment update and overview of 2013 major corporate milestones, in a presentation at the 31
st Annual J.P. Morgan Healthcare Conference in San Francisco. A webcast replay of the presentation, which was delivered today, January 10, at 12:00 PM Pacific Time, is archived on the Sunesis website at
http://ir.sunesis.com and will be available for two weeks.
"Last year was a very productive period for Sunesis, with meaningful progress in our vosaroxin studies, including our pivotal, Phase 3 VALOR trial," said Daniel Swisher, Chief Executive Officer of Sunesis. "Looking ahead in 2013, we see a number of value-creating milestones, particularly with the advancement of vosaroxin toward commercialization. It is our goal to see vosaroxin, an unpartnered asset and one of the most advanced and promising therapies in development for AML today, change the global standard of care in this disease. With continued support and enthusiasm from our investigators and stakeholders, as well as a strong balance sheet, we remain well positioned to achieve this goal."